Barclays set a $20.00 price target on Teva Pharmaceutical Industries (NYSE:TEVA) in a report released on Thursday morning, MarketBeat.com reports. The firm currently has a hold rating on the stock.
Several other research analysts also recently commented on the company. Cantor Fitzgerald set a $18.00 target price on Teva Pharmaceutical Industries and gave the stock a hold rating in a report on Thursday, May 17th. Credit Suisse Group set a $23.00 target price on Teva Pharmaceutical Industries and gave the stock a buy rating in a report on Monday, May 14th. Zacks Investment Research raised Teva Pharmaceutical Industries from a sell rating to a hold rating in a report on Wednesday, May 9th. Oppenheimer reissued a hold rating on shares of Teva Pharmaceutical Industries in a report on Monday, May 7th. Finally, Morgan Stanley reissued a hold rating and issued a $18.00 target price on shares of Teva Pharmaceutical Industries in a report on Monday, May 7th. Ten research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and six have assigned a buy rating to the company. Teva Pharmaceutical Industries has a consensus rating of Hold and an average target price of $19.86.
Shares of Teva Pharmaceutical Industries opened at $22.18 on Thursday, according to MarketBeat. The company has a market capitalization of $22.00 billion, a PE ratio of 5.64, a price-to-earnings-growth ratio of 1.77 and a beta of 0.67. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.65 and a current ratio of 1.00. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $33.82.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, May 3rd. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.63 by $0.28. The business had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.80 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.59% and a negative net margin of 72.36%. Teva Pharmaceutical Industries’s revenue was down 10.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.06 EPS. sell-side analysts expect that Teva Pharmaceutical Industries will post 2.45 EPS for the current fiscal year.
In related news, Director Roberto Mignone purchased 750,000 shares of the business’s stock in a transaction dated Thursday, May 10th. The shares were bought at an average price of $19.24 per share, with a total value of $14,430,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 5,684 shares of company stock worth $105,411. 0.43% of the stock is currently owned by company insiders.
Several hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 8.2% in the 4th quarter. Franklin Resources Inc. now owns 79,488,139 shares of the company’s stock valued at $1,506,309,000 after purchasing an additional 6,009,897 shares during the period. Polaris Capital Management LLC lifted its stake in shares of Teva Pharmaceutical Industries by 10.1% in the 1st quarter. Polaris Capital Management LLC now owns 9,824,274 shares of the company’s stock valued at $167,897,000 after purchasing an additional 897,368 shares during the period. Two Sigma Advisers LP acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $118,487,000. OppenheimerFunds Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 15.5% in the 1st quarter. OppenheimerFunds Inc. now owns 4,229,508 shares of the company’s stock valued at $72,282,000 after purchasing an additional 566,300 shares during the period. Finally, Thornburg Investment Management Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 37.2% in the 1st quarter. Thornburg Investment Management Inc. now owns 3,808,527 shares of the company’s stock valued at $65,088,000 after purchasing an additional 1,032,302 shares during the period. 64.73% of the stock is currently owned by institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.